BioCentury | Jul 23, 2020
Emerging Company Profile

On track for 2021 launch, Seer unveils unbiased proteomics tech and latest $55M round

With a fresh $55 million and a new publication detailing its nanoparticle-based technology, Seer thinks it can bring the scale and speed of next-generation sequencing to proteomics next year. On Wednesday, Seer announced a series...
BioCentury | Feb 16, 2017
Translation in Brief

A wrinkle in prion

A form of fatal encephalitis called variant Creutzfeldt-Jakob disease has been transmitted through blood transfusions at least four times in the U.K. because no test exists that can screen blood samples for the misfolded prion...
BioCentury | Jan 26, 2015
Clinical News

Syphilis Health Check regulatory update

...FDA granted a CLIA waiver to Diagnostics Direct’s Syphilis Health Check test to detect syphilis. The point-of-care...
...rapid membrane immunochromatographic assay detects Treponema pallidum antibodies in human whole blood, serum or plasma. Diagnostics Direct...
...the Trinity Biotech USA division of Trinity Biotech plc (NASDAQ:TRIB, Dublin, Ireland) co-market the test. Diagnostics Direct LLC...
BioCentury | Jun 2, 2014
Company News

True Diagnostics, Merck KGaA deal

True Diagnostics granted Merck's EMD Serono Inc. subsidiary exclusive rights to commercialize True Diagnostics' TrueDx Platform for use with TrueDX-TSH test in China, where the products are approved. TrueDX-TSH uses Lateral Flow Immunoassay technology to...
BioCentury | Dec 6, 2010
Regulation

New Diagnostics Pathway

FDA and members of Congress are putting the finishing touches on different proposals to create a new regulatory pathway for diagnostics, making it almost certain that major changes will be unveiled in 2011. The question...
BioCentury | Jun 21, 1993
Company News

NeXagen deal

Becton Dickinson took a $5 million equity position in NeXagen, in addition to funding undisclosed research costs. Patrick Mahaffy, president and CEO at privately held NeXagen, said the companies hope to develop technologies that eventually...
Items per page:
1 - 6 of 6
BioCentury | Jul 23, 2020
Emerging Company Profile

On track for 2021 launch, Seer unveils unbiased proteomics tech and latest $55M round

With a fresh $55 million and a new publication detailing its nanoparticle-based technology, Seer thinks it can bring the scale and speed of next-generation sequencing to proteomics next year. On Wednesday, Seer announced a series...
BioCentury | Feb 16, 2017
Translation in Brief

A wrinkle in prion

A form of fatal encephalitis called variant Creutzfeldt-Jakob disease has been transmitted through blood transfusions at least four times in the U.K. because no test exists that can screen blood samples for the misfolded prion...
BioCentury | Jan 26, 2015
Clinical News

Syphilis Health Check regulatory update

...FDA granted a CLIA waiver to Diagnostics Direct’s Syphilis Health Check test to detect syphilis. The point-of-care...
...rapid membrane immunochromatographic assay detects Treponema pallidum antibodies in human whole blood, serum or plasma. Diagnostics Direct...
...the Trinity Biotech USA division of Trinity Biotech plc (NASDAQ:TRIB, Dublin, Ireland) co-market the test. Diagnostics Direct LLC...
BioCentury | Jun 2, 2014
Company News

True Diagnostics, Merck KGaA deal

True Diagnostics granted Merck's EMD Serono Inc. subsidiary exclusive rights to commercialize True Diagnostics' TrueDx Platform for use with TrueDX-TSH test in China, where the products are approved. TrueDX-TSH uses Lateral Flow Immunoassay technology to...
BioCentury | Dec 6, 2010
Regulation

New Diagnostics Pathway

FDA and members of Congress are putting the finishing touches on different proposals to create a new regulatory pathway for diagnostics, making it almost certain that major changes will be unveiled in 2011. The question...
BioCentury | Jun 21, 1993
Company News

NeXagen deal

Becton Dickinson took a $5 million equity position in NeXagen, in addition to funding undisclosed research costs. Patrick Mahaffy, president and CEO at privately held NeXagen, said the companies hope to develop technologies that eventually...
Items per page:
1 - 6 of 6